Ralmitaront clinical trials
Also written RO6889450.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses ralmitaront is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 2 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses ralmitaront is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- 18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With SchizophreniaCompletedPhase 1Hoffmann-La RocheNCT06880328Written as Ralmitaront
- A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative SymptomsTerminatedPhase 2Hoffmann-La RocheNCT03669640Written as RO6889450
- A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective DisorderCompletedPhase 2Hoffmann-La RocheNCT04512066Written as RO6889450
- The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RO6889450 in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT02699372Written as RO6889450
Codes
What other systems call ralmitaront · ClinicalTrials.gg INT017669
- UNII (FDA) QA8MW1Q80PRALMITARONTConfirmed FDA, Wikidata
- Wikidata Q108226466ralmitarontConfirmed FDA, Wikidata
- NCI Thesaurus C171734RalmitarontOne source FDA
- DrugBank DB19128One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | QA8MW1Q80P | RALMITARONT | Confirmed FDA, Wikidata |
| Wikidata | Q108226466 | ralmitaront | Confirmed FDA, Wikidata |
| NCI Thesaurus | C171734 | Ralmitaront | One source FDA |
| DrugBank | DB19128 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.